Neurocrine Biosciences | NBIX - Current Assets


Neurocrine Biosciences reported $2.44B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
AbbVie USD 33.53B 4.47B Mar/2026
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Agios Pharmaceuticals USD 834.84M 107.21M Mar/2026
ALKERMES USD 1.36B 570.52M Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Cytokinetics USD 839.46M 77.51M Mar/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Exelixis USD 1.21B 234.65M Mar/2026
Gilead Sciences USD 18.64B 1.25B Mar/2026
Halozyme Therapeutics USD 1B 177.83M Mar/2026
Incyte USD 5.48B 460.36M Mar/2026
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Prothena USD 339.2M 24.01M Mar/2026
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Repligen USD 1.16B 23.98M Mar/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Teva Pharmaceutical Industries USD 13.71B 236M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026
Xoma USD 110.71M 5.78M Sep/2025